# A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

> **NCT00210470** · PHASE2 · COMPLETED · sponsor: **Brooklyn ImmunoTherapeutics, LLC** · enrollment: 27 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** IRX-2
- **DRUG:** Cyclophosphamide
- **DRUG:** Indomethacin
- **DRUG:** Zinc
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT00210470
- **Lead sponsor:** Brooklyn ImmunoTherapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2010-12
- **Final completion:** 2012-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210470, "A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00210470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*